Investing.com -- DoorDash agreed to acquire grocery-delivery rival Instacart for approximately $17 billion, confirming takeover speculation that sent Instacart shares higher earlier this week while weighing on DoorDash stock.
Under the definitive agreement announced Thursday, DoorDash will pay $65 per Instacart share, with at least 75% of the consideration in cash. Instacart shareholders can elect cash, DoorDash stock or a combination, subject to proration and a cap on... (continue reading...)
Investing.com -- Shares of Iovance Biotherapeutics (NASDAQ: IOVA) initially dropped 15% before recovering to a 6% loss on Thursday after the company shared updated trial results for its lung cancer therapy, lifileucel.
The trial focused on patients with advanced lung cancer whose disease had continued to spread despite exhausting standard treatments like chemotherapy and immunotherapy. Out of 69 total patients, about 25% saw their tumors shrink or disappear—a result... (continue reading...)
Investing.com -- L3Harris on Thursday beat third-quarter profit and revenue estimates and raised its 2026 earnings and revenue outlook, though its shares slipped 1% in premarket trading.
The U.S. defense contractor posted adjusted earnings per share of $3.28, ahead of the $2.96 analysts expected. Revenue rose about 7% to $6.06 billion, also above the $5.93 billion consensus.
L3Harris now expects 2026 earnings per share of $12.25 to $12.35, up from $11.80 to $12.00 and... (continue reading...)
Investing.com -- Bristol Myers Squibb (NYSE: BMY) reported third-quarter results before the open on Thursday, exceeding analyst expectations.
Adjusted earnings per share of $1.35 beat the consensus estimate of $1.09 by $0.26. Revenue reached $13.07 billion, surpassing the $12.72 billion analyst estimate and representing a 7% increase from $12.22 billion in the same quarter last year.
The company raised its full-year 2026 revenue guidance to a range of $49.75 billion to... (continue reading...)
Investing.com -- Merck shares rose more than 2% in premarket trading Thursday after the drugmaker beat third-quarter estimates and raised its 2026 earnings outlook. Earnings per share were $2.49, ahead of the $2.09 analysts expected.
Revenue was $18.1 billion, up 4% excluding currency effects, and also above the consensus estimate of $17.28 billion.
Keytruda, the cancer immunotherapy that is Merck’s biggest product, had sales of $8.6 billion, up 6%. That includes $830... (continue reading...)
More Investing
View Older Stories-
Eli Lilly jumps on earnings beat, raised guidance
-
Cognizant shares down 8% in premarket trade as Q3 bookings drop
-
Norwegian Cruise Line stock jumps on earnings beat
-
Caterpillar earnings beat estimates amid rapid AI buildout
-
Carrier Global stock gains on earnings beat and strong guidance
-
Alphabet’s $9bn cash burn drags neocloud stocks lower
-
ECB’s Lagarde to resign in February 2027
-
BYD net profit jumps 28% in third quarter
-
Linde stock rises 3% on third-quarter earnings, revenue beats
-
TotalEnergies Q3 adjusted net income jumps 51% on refining margins, gas prices
-
DBV Technologies shares slide 8% on going-concern warning, wider Q3 loss
-
Alphabet, Microsoft earnings in focus; Warsh on AI, rates - what’s moving markets
-
WPP shares rise as Q3 underlying sales decline narrows, guidance held
-
UFP Industries falls on third quarter earnings miss
-
Fortinet raises 2026 revenue outlook after strong third-quarter print
-
Bausch Health soars on earnings beat and raised outlook
-
Microsoft rises premarket as cloud strength drives earnings beat
-
Chipotle gains on comp sales beat despite earnings miss
-
ServiceNow shares sink on earnings miss, weak Q4 revenue outlook
-
FedEx falls despite beating earnings expectations
-
KLA shares jump 3% on Q1 earnings beat and upgraded guidance
-
T-Mobile Q3 profit jumps 27% as revenue tops estimates
-
Carvana shares rise after Q3 revenue beats expectations
-
Alphabet shares tumble 10% as earnings miss overshadows cloud boom
-
Nvidia faces DOJ antitrust scrutiny over $12.9B Hugging Face deal, Reuters says
-
Moody’s cuts Whirlpool rating to B1 on housing slump and weak margins
-
Top independent power producers: Scotiabank picks
-
Fed’s Warsh to attend AI productivity task force hearing in November
-
Oracle shares jump as long-term outlook targets $225 billion in revenue
-
Fed holds rates steady as expected
-
Palantir defense chief says AI advances may force China to invade Taiwan
-
Anthropic to offer IPO shares to UK retail investors with RetailBook
-
Airbus Q3 revenue misses as deliveries slow; 2026 guidance kept
-
Apple unveils MacBook Pro with touchscreen OLED display
-
Google unveils Gemini 4 Carbon with advanced cybersecurity features
-
Top nuclear stocks to watch amid sector pullback, says B Riley
-
Moody’s cuts Cogent rating to Caa2 on mounting 2027 debt refinancing risks
-
GE Vernova meets high bar, but slot conversions now in focus: BNP Paribas
-
Cerebras Systems drops 4% following Culper Research short report
-
Visteon stock falls as CFO Jerome Rouquet set to depart
-
UBS Ranks Fertilizer Stocks as Nitrogen Outlook Improves
-
Clover Health climbs after Needham initiates coverage with Buy, $6 target
-
BofA clients dump communication services stocks at record pace after Meta slump
-
Jefferies upgrades Chemed to Buy, sees compounder multiple returning on Q3 beat
-
Houthis strike Aden airport after evacuation warning - Reuters
-
Canadian watchdog warns Air Canada-United deal may harm competition
-
Lam Research rises as SK Hynix reports record sales
-
Rivian shares slip ahead of Thursday earnings release
-
Tesla shares pull back as rally pauses
-
SpaceX stock drops amid spaceport lawsuit, debt concerns
